thromboxane-b2 and bumecain

Platelet aggregation, prostacyclin and thromboxane were studied in 35 individuals: 20 coronary patients with angina of effort and 15 high-risk patients before and after treatment with lidocaine and pyromecaine. Oral administration of lidocaine and pyromecaine pills considerably depresses platelet aggregation and even causes platelet disaggregation. However, lidocaine disaggregating effect is greater than that of pyromecaine. Both agents affect vascular hemostasis by reducing thrombaxane and raising prostacyclin levels. Hence, the anti-aggregant effect of anti-arrhythmic proocaines may be attributed to changes in vascular hemostasis. The results obtained are expanding the range of indications for the use of these drugs.

Topics: Adult; Aged; Anti-Arrhythmia Agents; Blood Platelets; Blood Vessels; Coronary Disease; Female; Hemostasis; Humans; Lidocaine; Male; Middle Aged; Platelet Aggregation; Prostaglandins F; Pyrrolidines; Thromboxane B2; Time Factors